



## Complete Summary

---

### GUIDELINE TITLE

Dementia and movement disorders.

### BIBLIOGRAPHIC SOURCE(S)

Dormont D, Seidenwurm DJ, Davis PC, Brunberg JA, De La Paz RL, Hackney DB, Jordan JE, Karis JP, Mukherji SK, Turski PA, Wippold FJ II, Zimmerman RD, McDermott MW, Sloan MA, Expert Panel on Neurologic Imaging. Dementia and movement disorders. [online publication]. Reston (VA): American College of Radiology (ACR); 2007. 15 p. [86 references]

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Braffman B, Drayer BP, Anderson RE, Davis PC, Deck MD, Hasso AN, Johnson BA, Masaryk T, Pomeranz SJ, Seidenwurm D, Tanenbaum L, Masdeu JC. Dementia. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000 Jun;215(Suppl):525-33. [31 references]

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Dementia, including:

- Alzheimer's disease (AD)
- Frontotemporal dementia (FTD)
- Lewy body disease (DLB)
- Vascular dementia (VaD)
- Creutzfeldt-Jakob disease (CJD)
- Normal-pressure hydrocephalus (NPH)
- Huntington's disease (HD)
- Neurodegeneration with brain iron accumulation (NBIA)
- Parkinson's disease (PD)
- Multiple system atrophy (MSA)
- Progressive supranuclear palsy (PSP)
- Amyotrophic lateral disease (ALS)

## **GUIDELINE CATEGORY**

Diagnosis  
Evaluation

## **CLINICAL SPECIALTY**

Family Practice  
Geriatrics  
Internal Medicine  
Neurology  
Radiology

## **INTENDED USERS**

Health Plans  
Hospitals  
Managed Care Organizations  
Physicians  
Utilization Management

## **GUIDELINE OBJECTIVE(S)**

To evaluate the appropriateness of initial radiologic examinations for dementia

## **TARGET POPULATION**

Patients with dementia and movement disorders

## **INTERVENTIONS AND PRACTICES CONSIDERED**

1. Magnetic resonance imaging (MRI)
  - Head without contrast
  - Head with and without contrast
  - Spectroscopy, head
  - Functional MRI (fMRI), head
  - Spine without contrast
  - Spine with and without contrast

2. Magnetic resonance angiography (MRA) head and/or neck
3. Computed tomography (CT), head
  - Without contrast
  - With and without contrast
4. Fluorodeoxyglucose positron emission tomography (FDG-PET), head
5. Nuclear medicine (NUC)
  - Single photon emission computed tomography (SPECT)
  - Cisternography
6. Ultrasound (US) carotid duplex

## **MAJOR OUTCOMES CONSIDERED**

Utility of radiologic procedures in differential diagnosis of dementia and movement disorders

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

The guideline developer performed literature searches of recent peer-reviewed medical journals and the major applicable articles were identified and collected.

### **NUMBER OF SOURCE DOCUMENTS**

Not stated

### **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Not Given)

### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

Not stated

### **METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review with Evidence Tables

### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

One or two topic leaders within a panel assume the responsibility of developing an evidence table for each clinical condition, based on analysis of the current literature. These tables serve as a basis for developing a narrative specific to each clinical condition.

## **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus (Delphi)

### **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Since data available from existing scientific studies are usually insufficient for meta-analysis, broad-based consensus techniques are needed for reaching agreement in the formulation of the appropriateness criteria. The American College of Radiology (ACR) Appropriateness Criteria panels use a modified Delphi technique to arrive at consensus. Serial surveys are conducted by distributing questionnaires to consolidate expert opinions within each panel. These questionnaires are distributed to the participants along with the evidence table and narrative as developed by the topic leader(s). Questionnaires are completed by participants in their own professional setting without influence of the other members. Voting is conducted using a scoring system from 1-9, indicating the least to the most appropriate imaging examination or therapeutic procedure. The survey results are collected, tabulated in anonymous fashion, and redistributed after each round. A maximum of three rounds is conducted and opinions are unified to the highest degree possible. Eighty percent agreement is considered a consensus. This modified Delphi technique enables individual, unbiased expression, is economical, easy to understand, and relatively simple to conduct.

If consensus cannot be reached by the Delphi technique, the panel is convened and group consensus techniques are utilized. The strengths and weaknesses of each test or procedure are discussed and consensus reached whenever possible. If "No consensus" appears in the rating column, reasons for this decision are added to the comment sections.

### **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

Not applicable

### **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

### **METHOD OF GUIDELINE VALIDATION**

Internal Peer Review

### **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

#### ACR Appropriateness Criteria®

#### Clinical Condition: Dementia and Movement Disorders

#### Variant 1: Probable Alzheimer's disease.

Radiologic Procedure	Rating	Comments	RRL*
MRI head without contrast	8		None
MRI head without and with contrast	7	See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	6		Low
FDG-PET head	6	For problem solving.	High
NUC SPECT head	5	For problem solving.	High
CT head with and without contrast	4		Low
MRI spectroscopy head	4		None
fMRI head	2	For research purposes.	None
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

#### Variant 2: Possible Alzheimer's disease.

Radiologic Procedure	Rating	Comments	RRL*
MRI head without contrast	8		None
MRI head without and with contrast	8	See comments regarding contrast in text under "Anticipated Expectations."	None

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
FDG-PET head	7	For problem solving.	High
CT head without contrast	6		Low
NUC SPECT head	6	For problem solving.	High
CT head without and with contrast	5		Low
MRI spectroscopy head	4		None
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 3: Suspected vascular dementia or mixed vascular dementia and Alzheimer's disease.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head with and without contrast	8	See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	6		Low
FDG-PET head	6	For problem solving.	High
MRA head and or neck	6	See comments regarding contrast in text under "Anticipated Expectations."	None
CTA head and or neck	6		Low
US carotid duplex	6		None
CT head with and without contrast	5		Low
NUC SPECT head	5	For problem solving.	High

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI spectroscopy head	2		None
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 4: Frontotemporal dementia.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head without and with contrast	8	See comments regarding contrast in text under "Anticipated Expectations."	None
FDG-PET head	7	For problem solving.	High
CT head without contrast	6		Low
NUC SPECT head	6	For problem solving.	High
CT head without and with contrast	4		Low
MRI spectroscopy head	4		None
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 5: Dementia with Lewy bodies.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head without and with contrast	8	See comments regarding contrast in text under "Anticipated Expectations."	None
NUC SPECT head	7	For problem solving.	High
FDG-PET head	7	For problem solving.	High
CT head without contrast	6		Low
CT head without and with contrast	5		Low
MRI spectroscopy head	3		None
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 6: Suspected prion disease (Creutzfeld-Jakob, iatrogenic CJ or variant CJ).**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8	Include diffusion weighted imaging.	None
MRI head with and without contrast	8	Include diffusion weighted imaging. See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	6		Low
MRI spectroscopy head	5		None
CT head with and without contrast	5		Low

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
NUC SPECT head	5	For problem solving	High
FDG-PET head	5	For problem solving.	High
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 7: Suspected normal pressure hydrocephalus.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head with and without contrast	8	See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	6		Low
NUC cisternography	6	For problem solving.	Low
CT head with and without contrast	5		Low
MRI spectroscopy head	3		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 8: Suspected Huntington disease.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
-----------------------------	---------------	-----------------	-------------

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head without and with contrast	7	See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	5		Low
NUC SPECT head	5	For problem solving.	High
FDG-PET head	5	For problem solving.	High
MRI spectroscopy head	3		None
CT head without and with contrast	3		Low
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 9: Clinical features suggestive of neurodegeneration with brain iron accumulation (NBIA).**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head with and without contrast	7	See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	5		Low
CT head with and without contrast	4		Low
MRI spectroscopy head	3		None
fMRI head	3		None

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
NUC SPECT head	3	For problem solving.	High
FDG-PET head	3	For problem solving.	High
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 10: Parkinson's disease: typical clinical features and responds to levodopa.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	7	For problem solving.	None
MRI head with and without contrast	7	For problem solving. See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	6		Low
NUC SPECT head	6	For problem solving. Specific ligand.	High
FDG-PET head	6	For problem solving. Dopa PET.	High
CT head with and without contrast	5		Low
MRI spectroscopy head	3		None
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 11: Parkinsonian syndrome: atypical clinical features not responsive to levodopa.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI head without contrast	8		None
MRI head without and with contrast	7	See comments regarding contrast in text under "Anticipated Expectations."	None
NUC SPECT head	6	For problem solving.	High
FDG-PET head	6	For problem solving.	High
CT head without contrast	5		Low
CT head without and with contrast	4		Low
MRI spectroscopy head	3		None
fMRI head	2		None
<b><u>Rating Scale: 1=Least appropriate, 9=Most appropriate</u></b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

**Variant 12: Motor neuron disease.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI spine without contrast	8	May need multilevel imaging.	None
MRI head without contrast	8		None
MRI spine with and without contrast	7	May need multilevel imaging. See comments regarding contrast in text under "Anticipated Expectations."	None
MRI head with and without contrast	7	See comments regarding contrast in text under "Anticipated Expectations."	None
CT head without contrast	5		Low
CT head with and	4		Low

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
without contrast			
MRI spectroscopy head	3		None
NUC SPECT head	3	For problem solving.	High
FDG-PET head	3	For problem solving.	High
fMRI head	2		None
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

## **Summary of Literature Review**

### **Dementia**

Dementia affects approximately 7% of the general population older than 65 years, and 30% of people older than 80. It is a clinical state characterized by a significant loss of function in multiple cognitive domains that is not due to an impaired level of arousal. Diagnosis of dementia requires either: 1) assessing an individual's current level of cognitive function and documenting a higher level of intellectual function in the past, or 2) documenting a decline in intellectual function by examinations over time. Cognitive defects due to delirium, restricted brain lesions (e.g., aphasia), and psychiatric problems (e.g., depression) must be excluded.

Accurate diagnosis of the specific type of dementia is important given the current availability of therapies such as cholinesterase inhibitors for Alzheimer's disease (AD) that can delay institutionalization. Moreover, there is significant prognostic value in establishing a diagnosis as it enables the clinician to provide anticipatory guidance to the patient and family, to more accurately predict the future course, to facilitate legal and financial planning, and to assist with providing access to community resources.

#### *Alzheimer's Disease*

Alzheimer's disease is the most frequent type of dementia in the U.S. and most European countries, comprising about 50%-80% of subjects in various clinicopathological series. The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) have established the criteria for the definite, probable, and possible diagnosis of AD. Criteria for a definite diagnosis are histologic evidence of AD obtained from a biopsy or autopsy in the presence of

the clinical criteria for probable AD. Criteria for a diagnosis of probable AD include: 1) the insidious onset and progressive worsening of dementia; 2) prominent difficulty with memory (especially retention and retrieval of new material); 3) onset after age 60; 4) no focal signs or gait difficulties on neurologic examination, especially early in the course; and 5) exclusion of other causes of dementia due to systemic disorders or other intracranial disorders. To exclude other intracranial disorders that might cause dementia (including stroke, intra-axial or extra-axial tumors, subdural hematomas, hydrocephalus, and Creutzfeldt-Jakob disease), neuroimaging (magnetic resonance imaging [MRI] or computed tomography [CT]) should be performed. If available, MRI is preferable to CT because of its greater sensitivity in detecting most intracranial pathologies. From 80% to 85% of patients who meet the criteria for probable AD have histologic evidence of AD. However, a prospective neuropathological study has demonstrated that in a population older than 85 years, the prevalence of neuropathologically defined AD was at least two times higher (33%) than the prevalence of clinically diagnosed AD (16%).

Criteria for a diagnosis of possible AD include: 1) variations in the onset, presentation, or clinical course of typical AD, or 2) the presence of a second systemic or intracranial disorder sufficient to produce dementia, but which is not considered to be the cause of the dementia. In either of these scenarios, MRI or (CT, if MRI is unavailable) should be performed to determine whether the patient has other intracranial abnormalities. Patients with possible AD have a greater incidence of other significant intracranial pathologies detected on neuroimaging studies than patients with probable AD.

A new clinical entity, mild cognitive impairment (MCI), has been defined more recently. It is a cognitive decline greater than expected for an individual's age and education level but that does not interfere notably with activities of daily life. More than half of the patients with MCI progress to dementia within 5 years. The amnesic subtype of MCI may constitute a prodromal stage of AD.

The primary role of neuroimaging in the workup of patients with probable or possible AD is to exclude other significant intracranial abnormalities. It is important to evaluate critically the role of imaging in assessing dementias, because the cost of a false positive diagnosis of AD, especially in cases of MCI, are very high. Recent investigations document specific diagnostic neuroimaging features in AD, suggesting an additional direct role of neuroimaging. Positron emission tomography (PET) studies with fluorine-18-fluorodeoxyglucose (FDG) show characteristic reductions of regional glucose metabolic rates in patients with probable and definite AD in the parietal, temporal, and posterior cingulate regions. PET accurately discriminates AD patients from normal subjects with a sensitivity of 96% and specificity of 100%. Metabolic neuroimaging studies using FDG paradoxically suggest that hippocampal dysfunction is absent in AD and MCI, but more recently automated FDG-PET analysis has demonstrated reduced hippocampal metabolism in MCI and AD, suggesting that the previous negative results were due to methodological problems. Quantitative FDG-PET measures may improve prediction of the conversion to AD in patients with MCI. A new promising technique for diagnosing AD is the use of molecular imaging with PET to detect in vivo A $\beta$  amyloid in the brain of patients with AD. This has been achieved using the Pittsburgh compound-B (PIB). This method, however, is not widely available in clinical practice because of the very short half-life of this

compound. The American Academy of Neurology (AAN) consensus group did not recommend PET for diagnosing AD.

MRI-based volumetric measurements of the hippocampal formation are significantly smaller in patients with mild AD compared with controls and compared to patients with other forms of dementia. This finding correlates with a neuropathologic hallmark of AD, which is focal atrophy of the hippocampal formation. MRI volumetric calculations permit differentiation of controls from patients with AD accurately in 85%-100% of cases. Although it is not as accurate as MRI, CT also permits detection of hippocampal atrophy in AD patients. Medial temporal lobe atrophy has also been observed in MCI compared to cognitively normal individuals. The presence of this sign has a high predictive value for the progression to dementia. The AAN did not recommend quantitative volumetry of the hippocampus.

Regional cerebral blood flow determined using single photon emission computed tomography (SPECT) imaging with Tc-99m hexamethyl propylene amine oxime (HMPAO) shows bilateral temporoparietal or hippocampal hypoperfusion in patients with AD. Whether brain SPECT contributes substantially to diagnostic accuracy after a careful clinical examination using current diagnostic criteria is controversial. An evidence-based review performed by the AAN concluded that SPECT imaging cannot be recommended for either the initial or the differential diagnosis of suspected dementia because it has not demonstrated superiority to clinical criteria. PET imaging is also not recommended for routine use at this time.

Hydrogen-1 MR spectroscopy (MRS) may permit identification of mild to moderate AD with a specificity and sensitivity that suggest the potential for clinical usefulness. Studies of automated MRS for AD diagnosis have reported high sensitivity and moderate specificity. Prospective studies are still lacking to validate this method for diagnosing AD. Functional MRI, diffusion tensor MRI, and perfusion MRI have been used in AD and MCI patients but are still investigational tools at this time.

Of these neuroimaging tests, MR volumetric analysis of the hippocampal formation and PET assessment of regional glucose metabolism are the most diagnostic of AD. Determining the specific clinical applications of either of these studies in patients with probable or possible AD, MCI, or atypical dementias awaits additional investigation. In patients with a diagnosis of probable AD, either of these neuroimaging studies may permit the accuracy to increase from the 80%-85% range to the 90%-100% range, depending on the prevalence of the disorder in the subject population. In patients with possible AD or other atypical dementias, these neuroimaging studies may also permit a more accurate diagnosis. Volumetric MRI studies, PET studies, and possibly functional MRI likely will play an important role in the evaluation of new therapeutic drug strategies in AD.

### *Frontotemporal Dementia*

Frontotemporal dementia (FTD) is a neurodegenerative disorder commonly mistaken for AD. Pathologically, it includes a heterogeneous group of sporadic and familial neuropsychiatric disorders. Pick's disease is one of the neuropathological entities of FTD. Unlike AD, which increases in frequency with age, FTD is rare after

the age of 75. The Work Group on Frontotemporal Dementia and Pick's Disease reassessed clinical and neuropathological criteria for FTD in 2001.

The clinical criteria for FTD are:

- The development of behavioral or cognitive deficits manifested by either a) early and progressive change in personality, characterized by difficulty in modulating behavior, often resulting in inappropriate responses or activities, or b) early and progressive change in language, characterized by problems with expression of language or severe naming difficulty and problems with word meaning
- The deficits outlined in 1a or 1b cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning
- The course is characterized by a gradual onset and continuing decline in function
- The deficits outlined in 1a or 1b are not due to other nervous system conditions (e.g., cerebrovascular disease), systemic conditions (e.g., hypothyroidism), or substance-induced conditions
- The deficits do not occur exclusively during a delirium
- The disturbance is not better accounted for by a psychiatric diagnosis

MRI may show atrophy of the anterior temporal and frontal lobes. PET studies assessing regional glucose metabolism with FDG show the metabolic disturbance most prominent in the frontal and temporal lobes. SPECT studies assessing regional cerebral perfusion with HMPAO show frontal hypoperfusion. Although PET and SPECT could help to make the differential diagnosis between AD and FTD, they are not recommended for routine use at the present time.

### *Lewy Body Disease*

Dementia with Lewy bodies (DLB) has been recently identified among demented patients. This description has been driven by autopsy studies showing that 15%-25% of elderly demented patients have Lewy bodies in their brainstem and cortex. Among demented elderly, DLB may constitute the most common neurodegenerative pathologic subgroup after pure AD. Antemortem diagnosis of DLB is clinically useful because, 1) DLB is often characterized by a rapidly progressive clinical syndrome, 2) important risks are related to the use of neuroleptic medication, and 3) DLB patients may be particularly responsive to cholinesterase inhibitors.

The DLB consortium has defined criteria for probable and possible DLB disease and has updated them recently. Briefly, the criteria include central features (essential for the diagnosis of DLB), core features (two are necessary for the diagnosis of probable DLB, one for possible), suggestive features, and supportive features. Central features include: dementia; prominent memory impairment not necessarily present in the early stages but usually evident with progression; and deficits on tests of attention, executive function, and visuospatial ability. Core features include: fluctuating cognition, recurrent visual hallucinations, and spontaneous features of Parkinsonism. Functional imaging of the dopamine transporter (DAT) using SPECT can help to distinguish DLB from AD. DAT striatal activity is normal in AD and low in DLB. Occipital hypoperfusion has been

demonstrated using SPECT and occipital hypometabolism using PET. In patients with DLB, MRI shows a preservation of hippocampal and medial temporal lobe volume, no occipital lobe atrophy despite abnormality on functional imaging, and atrophy of the putamen.

Many patients with Parkinson's disease (PD) develop dementia (PDD), in most cases at least 10 years after onset of motor symptoms. The only differences between DLB and PDD are age at onset, temporal course, and possibly levodopa responsiveness. DLB should be diagnosed when dementia occurs before or concurrently with PD, and PDD should be diagnosed when dementia occurs in the context of well-established PD.

### *Vascular Dementia*

Vascular dementia (VaD) constitutes the second most common type of dementia. The main clinicopathological subtypes are large-vessel VaD and small-vessel VaD. Most patients with a diagnosis of VaD have small-vessel disease. VaD can be prevented or arrested by measures that prevent recurrent infarction (i.e., control of hypertension, antiplatelet therapy). Cognition may even improve after these factors are controlled suggesting that at least a portion of dementia is caused by reversible physiologic changes and not infarction. Therefore, clinical and radiologic tests that aid in distinguishing VaD from less treatable forms of dementia may be beneficial.

A diagnosis of VaD is supported by the following findings: 1) the sudden onset of dysfunction in one or more cognitive domains; 2) a stepwise deteriorating course; 3) focal neurologic signs, including weakness of an extremity, exaggeration of deep tendon reflexes, extensor plantar responses, and gait abnormalities; 4) evidence of stroke risk factors and systemic vascular disease; and 5) evidence of previous strokes. The role of neuroimaging, therefore, is to document the presence or absence of strokes. Reproducibility for the diagnosis of VaD among the different criteria is very low. At present the preferred diagnostic criteria for VaD for research protocols are those developed by the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN). They are probably the most specific, although their sensitivity is probably low. Interestingly, they include imaging criteria for the definition of VaD.

NINDS-AIREN criteria for diagnosing VaD define definite, probable, and possible VaD. The criteria for probable VaD include: dementia; cerebrovascular disease defined by the presence of focal signs and evidence of relevant cerebrovascular disease by brain imaging (CT or MRI); and a relationship between these two disorders. The NINDS-AIREN imaging criteria for VaD include multiple large-vessel infarcts; single strategically placed infarct; multiple basal ganglia; and white matter lacunes or extensive periventricular white matter lesions or combinations of both type of lesions (small-vessel disease). Precise operational definitions of MRI NINDS-AIREN criteria for VaD with interobserver study have been published. Although CT can detect the presence or absence of infarctions in patients with dementia, histopathologically verified cases of VaD with normal CT studies have been reported. Thus MRI is preferable to CT for detecting vascular lesions in patients with dementia.

Differentiation of VaD from either AD with superimposed cerebrovascular disease or mixed AD and VaD is especially difficult. When VaD is diagnosed, this pathologic diagnosis alone is confirmed in about 25% of cases; more commonly, a mixed disorder with neuropathologic changes of both AD and VaD is found. On neuroimaging studies, extensive infarctions (cortical or lacunar or both) and white-matter changes (hyperintense on T2-weighted MR images or hypodense on CT) in a patient with dementia favor a clinical diagnosis of VaD or mixed VaD and AD over AD. The absence or mild extent of these changes in a patient with dementia argues against a diagnosis of VaD.

FDG-PET in VaD shows multiple focal metabolic defects. Differentiation between AD and VaD is much better achieved by PET than by SPECT. SPECT is of little value in differentiating AD from VaD. Magnetic resonance spectroscopy (MRS) and functional MRI are investigational and, to date, do not appear to clinically help establish a diagnosis of VaD or mixed VaD and AD.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant hereditary small-artery vasculopathy caused by mutations in the notch3 gene on chromosome 19. Clinically, the disease is characterized by migraine with aura, strokes and progressive subcortical dementia, and mood disturbances. Usually, the disease begins around the age of 40 with mean disease duration of 20 years followed by death between the ages of 55 and 65. MRI in these patients shows focal lacunar infarcts and leukoaraiosis. Lesion load increases with age. Besides familial anamnesis and clinical history, structural MRI changes in these patients help to suggest the diagnosis by showing characteristic hyperintense T2 or FLAIR lesions which predominate in the frontal, parietal, and anterior temporal cortexes, and in the external capsule. Diagnosis is confirmed by skin biopsy or detection of a pathogenic notch3 mutation on direct sequencing.

#### *Creutzfeldt-Jakob-Disease*

Creutzfeldt-Jakob-Disease (CJD) is a fatal neurodegenerative disorder due to the accumulation of an abnormal form of the human prion protein PrP<sup>Sc</sup> in the brain. In humans there are three main forms of CJD: 1) sporadic CJD (sCJD) which affects patients between the ages of 50 and 75; 2) iatrogenic CJD; and 3) variant CJD (vCJD) which affect younger patients (average age of onset: 25-30 years). A definite diagnosis of CJD is based on histopathological findings; however, brain biopsy is rarely performed in patients with suspected CJD, and autopsy data are not always available. During life, the diagnosis of probable CJD can be made on the basis of clinical signs, including a rapidly progressive dementia associated with upper motor neuron dysfunction, myoclonus, characteristic EEG (generalized periodic sharp wave complexes), detection of 14-3-3 proteins in the cerebrospinal fluid (CSF) and neuroimaging findings. Although some variability exists, the most common MRI abnormality, other than progressive atrophy, is hyperintense signal on long-TR images in gray-matter structures, usually in the basal ganglia or thalami, and less commonly in the cortical gray matter. More recent MRI studies have demonstrated the value of diffusion-weighted imaging (DWI) in diagnosing CJD. Cortical abnormalities were present in 70 of 157 patients (45%) but were visible in 35 of 44 patients (80%) of the available DWI examinations. Basal ganglia were affected in 94 patients (60%), in particular in the caudate nucleus. The most sensitive sequences were DWI (64%) and PD-weighted (63%). It is

suggested that MRI helps to improve the diagnosis of CJD, and incorporation of MRI in the diagnostic criteria has been proposed for sCJD.

Marked cerebral hypometabolism on FDG-PET in the early stages of CJD, when no parenchymal abnormalities are present on MRI has been described. Similarly, focal hypoperfusion was detected with SPECT using Nisopropyl-(iodine-123) p-iodoamphetamine ( $I^{123}$ -IMP) before CT or MRI showed any abnormalities. Changes in cerebral metabolites using proton MRS have also been described in patients with CJD.

Variant CJD was described in humans for the first time in 1996. Strong evidence indicates transmission to humans of bovine spongiform encephalopathy (BSE) via ingestion of contaminated beef products. As of August 2006 there have been only 2 human cases in the United States, but 162 cases have been observed in the United Kingdom and 20 in France. In contrast to sCJD, vCJD affects younger patients and has a relatively longer duration of illness (median of 14 months as opposed to 4.5 months). In the appropriate clinical context, bilateral hypersignal on a T2-weighted MRI sequence at the level of the pulvinar (pulvinar sign) has been described as a useful noninvasive test for diagnosing vCJD. Histological confirmation of a diagnosis of vCJD can be obtained using tonsil biopsy.

#### *Normal-Pressure Hydrocephalus*

Normal-pressure hydrocephalus (NPH) is characterized by the clinical triad of dementia, gait disturbance, and urinary incontinence. Other diagnostic features include normal cerebrospinal fluid (CSF) pressure at lumbar puncture, communicating hydrocephalus documented on MRI or CT, and ventricular influx but no passage of isotope over the convexities on radionuclide cisternography (RC).

Because the dementia and other symptoms can be reversible with shunting, and because patients with NPH who are not shunted may progress symptomatically, distinction between responders and nonresponders is important. Several clinical, laboratory, and imaging signs may improve distinction between responders and nonresponders to shunting. Clinical features that favor shunt responsiveness include predominance of gait disturbance, mild to moderate degree of dementia, and rapid clinical progression of urinary incontinence. MRI or CT findings include at least moderate ventriculomegaly (with rounded frontal horns and marked enlargement of the temporal horns and third ventricle), and absence of or only mild cortical atrophy. Increased CSF flow void through the cerebral aqueduct on MRI appears to correlate with a good response to shunt surgery. Cine MRI with inflow technique showing hyperdynamic aqueductal CSF may also help in identifying shunt-responsive NPH patients. SPECT cisternography permits more accurate localization of radionuclide activity than planar cisternography, which partially superimposes different CSF compartments. One study using quantitative RC with SPECT found that a higher relative count value in the lateral and third ventricles was predictive for the patient responding to shunt surgery.

Recently, evidence-based guidelines have been developed by the INPH guidelines study group for diagnosing idiopathic normal pressure hydrocephalus (INPH). In these guidelines, the patients are divided into probable INPH, possible INPH, or unlikely INPH. Brain imaging features for diagnosing probable INPH include:

ventricular enlargement not entirely attributable to cerebral atrophy or congenital enlargement (Evan's index = maximal width of frontal horns/maximal width of inner skull >0.3); no macroscopic obstruction of CSF flow; and at least one the following features: enlargement of the temporal horns, callosal angle of 40° or more, evidence of altered brain water content, and aqueductal or fourth ventricle flow void on MRI. Other brain imaging findings, considered as supportive of the diagnosis but not necessary for probable INPH are: brain imaging performed before onset of symptoms showing smaller ventricular size; radionuclide cisternogram showing delayed clearance of radiotracer over the cerebral convexities; cine MRI study showing increased ventricular flow rate; and a SPECT acetazolamide challenge showing decreased periventricular perfusion that is not altered by acetazolamide.

In conclusion, dementia is a major cause of disability and death in developed countries. The impact of a demented patient on his or her family is substantial. Neuroimaging studies play a critical role in the evaluation of dementia to rule out structural causes that may be reversible and to contribute to the diagnosis of specific types of dementia with important therapeutic and prognostic implications.

### **Degenerative Diseases of the Extrapyramidal System**

The extrapyramidal centers are large subcortical nuclear structures from which output systems emerge at several points. Since mediation and control of the corticospinal tract are the most prominent functions of these output systems, lesions of the extrapyramidal nuclei typically result in motor dysfunction of various types.

#### *Huntington's Disease*

The usual age of onset of Huntington's disease (HD) is in the 4th and 5th decades. It is inherited in an autosomal dominant fashion with complete penetrance. Clinical manifestations are choreoathetosis, rigidity, dementia, and emotional disturbance. The Huntington disease phenotype results from an expanded cytosine, adenine, guanine (CAG) trinucleotide repeat within the *IT15* gene located on chromosome 4. The discovery of this mutation permits genetic testing to confirm the diagnosis of HD, and also to identify presymptomatic subjects who will develop the disease later in life.

Neuroimaging and pathology studies both show characteristic atrophy of the caudate and/or putamen. MR also shows signal changes of the striatum, either hyperintensity or hypointensity on long-TR or long-TE images. Neuronal loss accompanied by loss of myelin and gliosis likely results in the hyperintense signal, while iron accumulation likely accounts for the hypointense signal. Using voxel-based morphometry, it has been shown that patients with HD have significant volume reductions in almost all brain structures, including total cerebrum, total white matter, cerebral cortex, caudate, putamen, globus pallidus, amygdala, hippocampus, brainstem, and cerebellum when compared with healthy age matched controls.

Localized <sup>1</sup>H nuclear magnetic resonance (NMR) spectroscopic studies have found increased lactate concentrations in the occipital cortex of symptomatic HD patients when compared with normal controls. Modification of activation pattern

has been demonstrated using functional MRI (fMRI) during a time discrimination task in presymptomatic HD compared to control subjects. SPECT studies show hypometabolism of the striatum in HD and in other types of chorea. Progressive striatal and cortical dopamine receptor dysfunction in HD has been shown using (11) C-raclopride PET scans.

### *Neurodegeneration with Brain Iron Accumulation*

Neurodegeneration with brain iron accumulation (NBIA) is a heterogeneous group of disorders characterized by neurodegeneration and excessive iron deposition in the basal ganglia. The old name for this syndrome is Hallervorden Spatz disease (HSD). This eponymous term has fallen into disfavor because of the unethical activities of J. Hallervorden, a German neuropathologist, during World War II. There are two types of NBIA: 1) early onset, rapidly progressive (classic) disease and 2) late onset, slowly progressive (atypical) disease. Clinically, the disorder is characterized by relentless progression of gait impairment, rigidity, dystonic posturing, and mental deterioration. The defective gene that causes most cases of NBIA was identified recently. Most patients with NBIA and all of those with the early-onset, rapidly progressive type, have mutations in the gene encoding pantothenate kinase 2 (PANK 2). Moreover, there is a striking correlation between MRI findings in NBIA and the presence or absence of PANK 2 mutations. All patients with the PANK 2 mutation show bilateral areas of hyperintensity within a hypointense zone in the medial globus pallidus on T2-weighted images. This pattern has been described as the "eye of tiger."

### *Parkinsonism*

Primary Parkinsonism syndromes include: Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). They include the disorders previously called striatonigral degeneration (SND), sporadic olivopontocerebellar atrophy (OPCA), and the Shy-Drager syndrome. A diagnosis of idiopathic PD is usually based on patient history and physical examination alone. A significant and lasting clinical response to dopaminergic therapy is also a key criterion for diagnosing idiopathic PD. A differentiating between idiopathic PD and MSA can be difficult early in the course of the disease, with up to 30% of MSA patients responding to levodopa in a short period. Imaging data may also be helpful in differentiating MSA from idiopathic PD in difficult cases.

### *Parkinson's Disease*

Idiopathic Parkinson's disease is relatively common. Between 2%-3% of the population may be expected to develop Parkinsonism at some time during life. The age of onset usually ranges between 50 and 60 years.

The neuropathologic hallmarks are loss of neuromelanin-containing neurons, gliosis and Lewy body formation in the substantia nigra (mainly the pars compacta), the locus nucleus, the dorsal nucleus of the vagus, and the substantia innominata. A diminution of the width of the pars compacta on MRI has been described in PD patients compared to controls with overlap between groups. This diminished width is thought to reflect selective neuronal loss of the pars compacta. Other authors have found a normal appearance of the substantia nigra on T2-weighted images in a majority of PD patients.

Proton MR spectroscopic studies found an increase in lactate in the occipital lobe in patients with Parkinson's disease compared to controls. <sup>18</sup>F-dopa PET can detect frontal changes in Parkinson's disease and preclinical disease in 30% of asymptomatic adult relatives of familial cases. Single-photon-emission computed tomography (SPECT) with <sup>123</sup>I-iodobenzamide predicts dopaminergic responsiveness in patients with Parkinsonism. More recently, it has been demonstrated that FDG-PET performed at the time of initial referral for Parkinsonism accurately predicted the clinical diagnosis of individual patients made at subsequent follow-up.

### *Multiple System Atrophy*

The discovery in 1989 of glial cytoplasmic inclusions (GCI) in the brain of patients with multiple system atrophy (MSA) provided a pathological marker for the disorder and confirmed that SND, OPCA, and Shy- Drager syndrome are the same disease with different clinical expression. Criteria for diagnosing MSA have been defined by a multidisciplinary panel. MSA can present with autonomic or motor deficits. The predominant motor deficit can be cerebellar (MSA-C = olivopontocerebellar atrophy) or parkinsonism (MSA-P = striatonigral degeneration). MSA-P is characterized clinically by Parkinsonian symptoms with prominence of rigidity and with an absent or poor response to anti-Parkinson medication.

Neuroimaging and gross pathology show atrophy of the striatum due to neuronal loss, with the putamen more involved than the caudate. At 1.5T, long-TR, long-TE images show putaminal hypointensity, particularly along its posterolateral margin, equal to or more evident than pallidal hypointensity. The degree of hypointense signal correlates significantly with the severity of rigidity. The hypointense signal is due to the paramagnetic effect of iron. PET with <sup>18</sup>F-dopa is useful in differentiating between PD and MSA.

More recently, hypointense putaminal signal changes on T2\* sequences have been described in MSA more often than in PD but not on T2-weighted images. These discrepancies between the results of recent studies and previous results are probably due to the evolution of MRI sequences currently employed. Fast spin-echo (SE) sequences are far less sensitive to magnetic susceptibility than SE T2-weighted sequences used in 1986. In a recent study of 230 Japanese patients with MSA, a hyperintense rim at the lateral edge of the dorsolateral putamen was seen on MRI in 34.5% of cases, and a "hot cross bun" sign in the pontine basis (PB) in 63.3%. These putaminal and pontine abnormalities became more prominent as MSA-P and MSA-C features advanced.

### *Progressive Supranuclear Palsy*

Progressive supranuclear palsy (PSP), also called Steele- Richardson-Olszewski syndrome, is one of the most common atypical Parkinsonian syndromes. To improve the specificity and sensitivity of the clinical diagnosis of PSP, the NINDS and the Society for PSP have developed a set of diagnostic criteria for this disorder. There are three degrees of diagnostic certainty: possible, probable, and definite. Possible PSP requires a gradually progressive disorder with onset at age 40 or later, either vertical supranuclear gaze palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of onset.

Probable PSP requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset.

Putaminal hypointensity has been described in PSP patients at 1.5T, using long-TR and long-TE sequences. The periaqueductal region of the midbrain is also implicated in the pathology of PSP. Some patients show slight hyperintense signal on the long-TR sequences of the periaqueductal gray matter. It has been shown that anteroposterior diameters of the suprapontine midbrain measured on axial T2-weighted MRI in patients with PSP were significantly lower than those of patients with PD and in control subjects without any overlap between these two groups. Other authors have demonstrated that the average midbrain area of patients with PSP measured on midsagittal MRI was significantly smaller than that of the patients with PD and MSA-P and that of an age-matched control group.

### **Degenerative Diseases of the Motor System**

Motor neuron diseases are a heterogeneous group of syndromes in which the upper and/or lower motor neurons degenerate. Amyotrophic lateral sclerosis (ALS) is the most frequent type of motor neuron disease, with an annual incidence rate of 0.4 to 1.76 per 100,000 people. Most patients are 50 years of age or older at the onset of symptoms. The disorder progresses relentlessly; about half the patients are dead within 3 years and 90% within 6 years.

ALS is characterized predominantly by degeneration of the corticospinal tract and lower motor neurons. The extent of corticospinal tract degeneration varies along the neuraxis. It can usually be traced from the lower portion of the spinal cord up through the medulla. Occasionally, degeneration of motor fibers proceeds farther cephalad sequentially through the pyramidal tracts of the brainstem and cerebral peduncles, the posterior part of the posterior limb of the internal capsule, and corona radiata, to the motor cortex. On MRI, atrophy and hyperintense foci of the corticospinal tract is seen on long-TR sequences. This high signal likely reflects characteristic histologic changes of myelin loss and gliosis. Hypointense signal on long-TR and long-TE sequences may also be found in ALS, due to iron deposition. The anterior and lateral portions of the cord may be atrophic and flattened due to loss of motor neurons in the anterior horns and corticospinal tracts. Magnetization transfer measurements are useful for detecting abnormalities associated with degeneration of the pyramidal tract in patients with ALS.

Proton magnetic resonance spectroscopy reveals decreased N-acetyl aspartate values in the sensorimotor cortex and brainstem of patients with ALS, consistent with neuronal dysfunction or loss. Involvement of the corticospinal tract in patients with ALS has been demonstrated using diffusion tensor imaging even at an early stage.

### **Anticipated Exceptions**

Nephrogenic systemic fibrosis (NSF, also known as nephrogenic fibrosing dermopathy) was first identified in 1997 and has recently generated substantial concern among radiologists, referring doctors and lay people. Until the last few years, gadolinium-based MR contrast agents were widely believed to be almost universally well tolerated, extremely safe and non-nephrotoxic, even when used in patients with impaired renal function. All available experience suggests that these

agents remain generally very safe, but recently some patients with renal failure who have been exposed to gadolinium contrast agents (the percentage is unclear) have developed NSF, a syndrome that can be fatal. Further studies are necessary to determine what the exact relationships are between gadolinium-containing contrast agents, their specific components and stoichiometry, patient renal function and NSF. Current theory links the development of NSF to the administration of relatively high doses (e.g., >0.2 mM/kg) and to agents in which the gadolinium is least strongly chelated. The FDA has recently issued a "black box" warning concerning these contrast agents ([http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca\\_200705HCP.pdf](http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705HCP.pdf)).

This warning recommends that, until further information is available, gadolinium contrast agents should not be administered to patients with either acute or significant chronic kidney disease (estimated GFR <30 mL/min/1.73m<sup>2</sup>), recent liver or kidney transplant or hepato-renal syndrome, unless a risk-benefit assessment suggests that the benefit of administration in the particular patient clearly outweighs the potential risk(s).

### **Abbreviations**

- CT, computed tomography
- CTA, computed tomography angiography
- FDG-PET, fluorodeoxyglucose positron emission tomography
- fMRI, functional magnetic resonance imaging
- MRI, magnetic resonance imaging
- MRA, magnetic resonance angiography
- MRI, magnetic resonance imaging
- NUC, nuclear medicine
- SPECT, single photon emission computed tomography
- US, ultrasound

### **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The recommendations are based on analysis of the current literature and expert panel consensus.

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Selection of appropriate radiologic imaging procedures for dementia and movement disorders

### **POTENTIAL HARMS**

- The relative radiation level is high for fluorodeoxyglucose positron emission tomography (FDG-PET) of the head and nuclear medicine (NUC) single photon emission computed tomography (SPECT) of the head; and low for computed tomography (CT) of the head without contrast, CT of the head with and without contrast, computed tomography angiography (CTA) of the head and or neck, and NUC cisternography.
- Some patients with renal failure who have been exposed to gadolinium contrast agents (the percentage is unclear) have developed nephrogenic systemic fibrosis, a syndrome that can be fatal. Until further information is available, gadolinium contrast agents should not be administered to patients with either acute or significant chronic kidney disease (estimated GFR <30 mL/min/1.73m<sup>2</sup>), recent liver or kidney transplant or hepato-renal syndrome, unless a risk-benefit assessment suggests that the benefit of administration in the particular patient clearly outweighs the potential risk(s).

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

An American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

### IMPLEMENTATION TOOLS

Personal Digital Assistant (PDA) Downloads

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better  
Living with Illness

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Dormont D, Seidenwurm DJ, Davis PC, Brunberg JA, De La Paz RL, Hackney DB, Jordan JE, Karis JP, Mukherji SK, Turski PA, Wippold FJ II, Zimmerman RD, McDermott MW, Sloan MA, Expert Panel on Neurologic Imaging. Dementia and movement disorders. [online publication]. Reston (VA): American College of Radiology (ACR); 2007. 15 p. [86 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

1996 (revised 2007)

### GUIDELINE DEVELOPER(S)

American College of Radiology - Medical Specialty Society

### SOURCE(S) OF FUNDING

The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria®.

### GUIDELINE COMMITTEE

Committee on Appropriateness Criteria, Expert Panel on Neurologic Imaging

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

*Panel Members:* Didier Dormont MD; David J. Seidenwurm, MD; Patricia C. Davis, MD; James A. Brunberg, MD; Robert Louis De La Paz, MD; David B. Hackney, MD; John E. Jordan, MD; John P. Karis, MD; Suresh Kumar Mukherji, MD; Patrick A.

Turski, MD; Franz J. Wippold II, MD; Robert D. Zimmerman, MD; Michael W. McDermott, MD; Michael A. Sloan, MD, MS

## **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

## **GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates a previous version: Braffman B, Drayer BP, Anderson RE, Davis PC, Deck MD, Hasso AN, Johnson BA, Masaryk T, Pomeranz SJ, Seidenwurm D, Tanenbaum L, Masdeu JC. Dementia. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000 Jun;215(Suppl):525-33. [31 references]

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

## **GUIDELINE AVAILABILITY**

Electronic copies: Available in Portable Document Format (PDF) from the [American College of Radiology \(ACR\) Web site](#).

ACR Appropriateness Criteria® *Anytime, Anywhere*™ (PDA application). Available from the [ACR Web site](#).

Print copies: Available from the American College of Radiology, 1891 Preston White Drive, Reston, VA 20191. Telephone: (703) 648-8900.

## **AVAILABILITY OF COMPANION DOCUMENTS**

The following are available:

- ACR Appropriateness Criteria®. Background and development. Reston (VA): American College of Radiology; 2 p. Electronic copies: Available in Portable Document Format (PDF) from the [American College of Radiology \(ACR\) Web site](#).
- ACR Appropriateness Criteria®. Relative radiation level information. Reston (VA): American College of Radiology; 2 p. Electronic copies: Available in Portable Document Format (PDF) from the [American College of Radiology \(ACR\) Web site](#).

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This summary was completed by ECRI on July 31, 2001. The information was verified by the guideline developer as of August 24, 2001. This NGC summary was updated by ECRI Institute on December 21, 2008.

## **COPYRIGHT STATEMENT**

Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria® may be found on the [ACR Web site](#).

## **DISCLAIMER**

### **NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/3/2008

